Abstract
The authors have advised there is an error in Table 1 on page 712. The value “1200 mg” in the Neisseria meningitidis vaccination row for the Induction Phase, Week 4 column for Refractory gMG Adult (≥18 years of age) Dosing Schedule, should read “900 mg”. This error was introduced by the Editorial staff during the publication process.
Cite
CITATION STYLE
Waheed, W., Newman, E., Aboukhatwa, M., Moin, M., & Tandan, R. (2022). Erratum to: Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review [Erratum] (Ther Clin Risk Manag. 2022;18:699–719). Therapeutics and Clinical Risk Management. Dove Medical Press Ltd. https://doi.org/10.2147/TCRM.S384532
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
